A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies
Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This study will be divided into two parts, Parts A and B and will enroll patients with
relapsed/refractory AML or MDS/chronic myelomonocytic leukemia (CMML) patients who have
failed up to 2 prior therapeutic regimens.
Part A is a dose escalation study to explore the safety, efficacy, pharmacokinetic (PK) and
pharmacodynamic (PD) profile of DSP107 when administered as monotherapy and in combination
with azacitidine (AZA).
Part B is a dose escalation study to explore the safety, efficacy, PK and PD profile of
DSP107 when administered in combination with AZA and venetoclax (VEN).